Precision Health at The Christ Hospital Health Network aims to transition healthcare delivery from reactive to proactive. Here we will discuss our approach to evaluating the impact of implementing precision health in every aspect of clinical care, from patient outcomes and satisfaction to physician participation to financial impact and health resource utilization. We have implemented precision health approaches ranging from proactive heritable disease risk evaluation for both cancer and cardiovascular disease with interactive ChatBots and genetic counseling/ testing (>30,000 pts evaluated in under two years, >7,000 identified with heritable disease risk) to system-wide pharmacogenomics to augmented intelligence-based clinical decision support. Critical to our success is ensuring complete integration of all things precision health into our electronic medical record as a single source of truth. We believe our approach to precision health will become a model for improved outcomes and value-based care initiatives. We are currently leading the first ever prospective, randomized, controlled trial of comprehensive pharmacogenomics. Preliminary data suggest reduction of ER visits, hospitalizations and 30-day readmissions by 30- 40%.
Burns C. Blaxall, PhD, is the founding Executive Director of Precision Health at The Christ Hospital Health Network (TCHHN). He leads a transition from reactive to proactive healthcare delivery by harnessing the power of personal diagnostic and genomic data. Using approaches ranging from cutting edge hereditary disease risk assessment, genetic counseling and testing to pharmacogenomics and genome-guided clinical care pathways, Precision Health at TCHHN aims to provide proactive, individualized care for every patient.
Share this page on your timeline